

Appendix 2: Outcome on CCG-2961															
Outcome from end of two courses															
	n	3 yr Overall Survival				3 yr Disease Free Survival				3 yr Relapse Free Survival					
		No Donor		Donor		No Donor		Donor		No Donor		Donor			
		No Donor	Donor	% (2 SE)	p-value	% (2 SE)	p-value	% (2 SE)	p-value	% (2 SE)	p-value	% (2 SE)	p-value	% (2 SE)	p-value
White	405	282 (69.6%)	123 (30.5%)	72% (6%)	0.002	72% (8%)	0.464	55% (6%)	0.014	62% (9%)	0.985	56% (6%)	0.073	74% (9%)	0.523
Black	57	53 (93.0%)	4 (7.0%)	50% (15%)	<0.001	50% (50%)	0.426	27% (13%)	<0.001	67% (54%)	0.831	29% (14%)	0.002	100% (0%)	0.384
Hispanic	97	75 (77.3%)	22 (22.7%)	65% (12%)	0.220	62% (21%)	0.386	54% (12%)	0.721	55% (22%)	0.572	58% (13%)	0.928	71% (22%)	0.845
Asian	15	10 (66.7%)	5 (33.3%)	50% (32%)	0.054	80% (36%)	0.566	38% (34%)	0.136	80% (36%)	0.355	43% (37%)	0.319	100% (0%)	0.215

Relapse free survival (RFS) events were defined as leukemia relapse, secondary malignancy, or death due to progressive disease. Non-progressive disease death was censored for RFS analyses.